185 related articles for article (PubMed ID: 36916290)
21. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.
Pietrantonio F; Caporale M; Morano F; Scartozzi M; Gloghini A; De Vita F; Giommoni E; Fornaro L; Aprile G; Melisi D; Berenato R; Mennitto A; Volpi CC; Laterza MM; Pusceddu V; Antonuzzo L; Vasile E; Ongaro E; Simionato F; de Braud F; Torri V; Di Bartolomeo M
Int J Cancer; 2016 Dec; 139(12):2859-2864. PubMed ID: 27578417
[TBL] [Abstract][Full Text] [Related]
22. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
[TBL] [Abstract][Full Text] [Related]
23. B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer.
Steenbruggen TG; Wolf DM; Campbell MJ; Sanders J; Cornelissen S; Thijssen B; Salgado RA; Yau C; O-Grady N; Basu A; Bhaskaran R; Mittempergher L; Hirst GL; Coppe JP; Kok M; Sonke GS; van 't Veer LJ; Horlings HM
Breast Cancer Res; 2023 Oct; 25(1):117. PubMed ID: 37794508
[TBL] [Abstract][Full Text] [Related]
24. Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.
Mishima Y; Matsusaka S; Chin K; Mikuniya M; Minowa S; Takayama T; Shibata H; Kuniyoshi R; Ogura M; Terui Y; Mizunuma N; Hatake K
Target Oncol; 2017 Jun; 12(3):341-351. PubMed ID: 28508152
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of PFKFB3 in HER2-positive gastric cancer improves sensitivity to trastuzumab by inducing tumour vessel normalisation.
Yao X; He Z; Qin C; Zhang P; Sui C; Deng X; Fang Y; Li G; Shi J
Br J Cancer; 2022 Sep; 127(5):811-823. PubMed ID: 35637411
[TBL] [Abstract][Full Text] [Related]
26. Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
Meulendijks D; Beerepoot LV; Boot H; de Groot JW; Los M; Boers JE; Vanhoutvin SA; Polee MB; Beeker A; Portielje JE; de Jong RS; Goey SH; Kuiper M; Sikorska K; Beijnen JH; Tesselaar ME; Schellens JH; Cats A
Invest New Drugs; 2016 Feb; 34(1):119-28. PubMed ID: 26643663
[TBL] [Abstract][Full Text] [Related]
27. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
Seo S; Ryu MH; Park YS; Ahn JY; Park Y; Park SR; Ryoo BY; Lee GH; Jung HY; Kang YK
Gastric Cancer; 2019 May; 22(3):527-535. PubMed ID: 30386954
[TBL] [Abstract][Full Text] [Related]
28. Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients.
Koh J; Nam SK; Lee YW; Kim JW; Lee KW; Ock CY; Oh DY; Ahn SH; Kim HH; Kang KW; Kim WH; Lee HY; Lee HS
Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31779184
[TBL] [Abstract][Full Text] [Related]
29. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
[TBL] [Abstract][Full Text] [Related]
30. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.
Qiu MZ; Li Q; Wang ZQ; Liu TS; Liu Q; Wei XL; Jin Y; Wang DS; Ren C; Bai L; Zhang DS; Wang FH; Li YH; Xu RH
Int J Cancer; 2014 May; 134(10):2468-77. PubMed ID: 24155030
[TBL] [Abstract][Full Text] [Related]
31. Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab.
Bang K; Cheon J; Park YS; Kim HD; Ryu MH; Park Y; Moon M; Lee H; Kang YK
Gastric Cancer; 2022 Jul; 25(4):794-803. PubMed ID: 35524883
[TBL] [Abstract][Full Text] [Related]
32. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.
Gomez-Martin C; Plaza JC; Pazo-Cid R; Salud A; Pons F; Fonseca P; Leon A; Alsina M; Visa L; Rivera F; Galan MC; Del Valle E; Vilardell F; Iglesias M; Fernandez S; Landolfi S; Cuatrecasas M; Mayorga M; Jose Paulés M; Sanz-Moncasi P; Montagut C; Garralda E; Rojo F; Hidalgo M; Lopez-Rios F
J Clin Oncol; 2013 Dec; 31(35):4445-52. PubMed ID: 24127447
[TBL] [Abstract][Full Text] [Related]
33. Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Nonagase Y; Yonesaka K; Kawakami H; Watanabe S; Haratani K; Takahama T; Takegawa N; Ueda H; Tanizaki J; Hayashi H; Yoshida T; Takeda M; Chiba Y; Tamura T; Nakagawa K; Tsurutani J
Oncotarget; 2016 Dec; 7(51):84860-84871. PubMed ID: 27768588
[TBL] [Abstract][Full Text] [Related]
34. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
Mezynski MJ; Farrelly AM; Cremona M; Carr A; Morgan C; Workman J; Armstrong P; McAuley J; Madden S; Fay J; Sheehan KM; Kay EW; Holohan C; Elamin Y; Rafee S; Morris PG; Breathnach O; Grogan L; Hennessy BT; Toomey S
J Transl Med; 2021 May; 19(1):184. PubMed ID: 33933113
[TBL] [Abstract][Full Text] [Related]
35. A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).
Kagawa S; Muraoka A; Kambara T; Nakayama H; Hamano R; Tanaka N; Noma K; Tanakaya K; Kishimoto H; Shigeyasu K; Kuroda S; Kikuchi S; Kuwada K; Nishizaki M; Shirakawa Y; Fujiwara T
Cancer Chemother Pharmacol; 2018 Feb; 81(2):387-392. PubMed ID: 29290024
[TBL] [Abstract][Full Text] [Related]
36. Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.
Pietrantonio F; Fucà G; Morano F; Gloghini A; Corso S; Aprile G; Perrone F; De Vita F; Tamborini E; Tomasello G; Gualeni AV; Ongaro E; Busico A; Giommoni E; Volpi CC; Laterza MM; Corallo S; Prisciandaro M; Antista M; Pellegrinelli A; Castagnoli L; Pupa SM; Pruneri G; de Braud F; Giordano S; Cremolini C; Di Bartolomeo M
Clin Cancer Res; 2018 Mar; 24(5):1082-1089. PubMed ID: 29208673
[No Abstract] [Full Text] [Related]
37. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
[TBL] [Abstract][Full Text] [Related]
38. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab.
Eto K; Iwatsuki M; Watanabe M; Ida S; Ishimoto T; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Ann Surg Oncol; 2014 Jan; 21(1):343-50. PubMed ID: 24154840
[TBL] [Abstract][Full Text] [Related]
39. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
[TBL] [Abstract][Full Text] [Related]
40. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.
Li Q; Li H; Jiang H; Feng Y; Cui Y; Wang Y; Ji Y; Yu Y; Li W; Xu C; Yu S; Zhuang R; Liu T
Clin Transl Oncol; 2018 Jun; 20(6):695-702. PubMed ID: 29168107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
